Cas no 115334-04-8 (Lanost-7-en-3-one,23,24-dihydroxy-25-methoxy-, (13a,14b,17a,20S,23R,24S)-)

Lanost-7-en-3-one,23,24-dihydroxy-25-methoxy-, (13a,14b,17a,20S,23R,24S)- structure
115334-04-8 structure
Product Name:Lanost-7-en-3-one,23,24-dihydroxy-25-methoxy-, (13a,14b,17a,20S,23R,24S)-
CAS No:115334-04-8
MF:C31H52O4
MW:488.742190361023
CID:205022
PubChem ID:189290
Update Time:2025-10-28

Lanost-7-en-3-one,23,24-dihydroxy-25-methoxy-, (13a,14b,17a,20S,23R,24S)- Chemical and Physical Properties

Names and Identifiers

    • Lanost-7-en-3-one,23,24-dihydroxy-25-methoxy-, (13a,14b,17a,20S,23R,24S)-
    • Phellochin
    • [ "" ]
    • (23R,24S)-23,24-Dihydroxy-25-methoxy-5α-tirucall-7-en-3-one
    • 24,25-Deepoxy-24-hydroxy-25-methoxyniloticin
    • (9R,10R,13S,14S,17R)-17-[(2S,4R,5S)-4,5-dihydroxy-6-methoxy-6-methylheptan-2-yl]-4,4,10,13,14-pentamethyl-1,2,5,6,9,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
    • F92884
    • 115334-04-8
    • (5R,9R,10R,13S,14S,17S)-17-[(2S,4R,5S)-4,5-Dihydroxy-6-methoxy-6-methylheptan-2-yl]-4,4,10,13,14-pentamethyl-1,2,5,6,9,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
    • DTXSID50921675
    • Lanost-7-en-3-one, 23,24-dihydroxy-25-methoxy-, (13alpha,14beta,17alpha,20S,23R,24S)-
    • 23,24-Dihydroxy-25-methoxylanost-7-en-3-one
    • (23R,24S)-23,24-Dihydroxy-25-methoxy-5alpha-tirucall-7-en-3-one
    • FS-10174
    • AKOS032961695
    • (1R,3aS,9aR,9bR,11aS)-1-[(2S,4R,5S)-4,5-dihydroxy-6-methoxy-6-methylheptan-2-yl]-3a,6,6,9a,11a-pentamethyl-1H,2H,3H,5H,5aH,8H,9H,9bH,10H,11H-cyclopenta[a]phenanthren-7-one
    • Inchi： 1S/C31H52O4/c1-19(18-23(32)26(34)28(4,5)35-9)20-12-16-31(8)22-10-11-24-27(2,3)25(33)14-15-29(24,6)21(22)13-17-30(20,31)7/h10,19-21,23-24,26,32,34H,11-18H2,1-9H3/t19-,20+,21-,23+,24?,26-,29+,30-,31+/m0/s1
    • InChI Key： OCURJKDUYAFAQG-RLXWAGRASA-N
    • SMILES： O=C1CC[C@@]2(C)C(CC=C3[C@@H]2CC[C@@]2(C)[C@@H]([C@@H](C)C[C@H]([C@@H](C(C)(C)OC)O)O)CC[C@@]23C)C1(C)C

Computed Properties

  • Exact Mass: 488.38700
  • Monoisotopic Mass: 488.38656014g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 2
  • Hydrogen Bond Acceptor Count: 4
  • Heavy Atom Count: 35
  • Rotatable Bond Count: 6
  • Complexity: 873
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 8
  • Undefined Atom Stereocenter Count : 1
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 6
  • Topological Polar Surface Area: 66.8?2

Experimental Properties

  • Color/Form: Powder
  • Density: 1.1±0.1 g/cm3
  • Boiling Point: 589.2±50.0 °C at 760 mmHg
  • Flash Point: 180.1±23.6 °C
  • PSA: 66.76000
  • LogP: 6.33370
  • Vapor Pressure: 0.0±3.7 mmHg at 25°C

Lanost-7-en-3-one,23,24-dihydroxy-25-methoxy-, (13a,14b,17a,20S,23R,24S)- Security Information

Lanost-7-en-3-one,23,24-dihydroxy-25-methoxy-, (13a,14b,17a,20S,23R,24S)- Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
P77790-5mg
Phellochin
 115334-04-8
5mg
 ￥4418.0 2021-09-08
TargetMol Chemicals
TN4762-5mg
Phellochin
 115334-04-8
5mg
 ￥ 4280 2024-07-19
TargetMol Chemicals
TN4762-5 mg
Phellochin
 115334-04-8 98%
5mg
 ￥ 4,280 2023-07-10
TargetMol Chemicals
TN4762-1 mL * 10 mM (in DMSO)
Phellochin
 115334-04-8 98%
1 mL * 10 mM (in DMSO)
 ￥ 4380 2023-09-15
TargetMol Chemicals
TN4762-1 ml * 10 mm
Phellochin
 115334-04-8
1 ml * 10 mm
 ￥ 4380 2024-07-19
A2B Chem LLC
AE17542-5mg
(23R,24S)-23,24-Dihydroxy-25-methoxy-5α-tirucall-7-en-3-one
 115334-04-8 ≥98%
5mg
 $1083.00 2024-04-20

Lanost-7-en-3-one,23,24-dihydroxy-25-methoxy-, (13a,14b,17a,20S,23R,24S)- Related Literature

Related Categories

Additional information on Lanost-7-en-3-one,23,24-dihydroxy-25-methoxy-, (13a,14b,17a,20S,23R,24S)-

Recent Advances in the Study of Lanost-7-en-3-one,23,24-dihydroxy-25-methoxy-, (13a,14b,17a,20S,23R,24S)- (CAS: 115334-04-8)

In recent years, the compound Lanost-7-en-3-one,23,24-dihydroxy-25-methoxy-, (13a,14b,17a,20S,23R,24S)- (CAS: 115334-04-8) has garnered significant attention in the field of chemical biology and pharmaceutical research. This lanostane-type triterpenoid, characterized by its unique stereochemistry and functional groups, has shown promising biological activities, including anti-inflammatory, anti-cancer, and immunomodulatory effects. The growing body of research on this compound underscores its potential as a lead molecule for drug development.

A recent study published in the *Journal of Medicinal Chemistry* explored the synthesis and biological evaluation of Lanost-7-en-3-one derivatives, with a focus on optimizing their pharmacological properties. The researchers employed a combination of chemical synthesis and computational modeling to design analogs with enhanced bioavailability and target specificity. The results demonstrated that the (13a,14b,17a,20S,23R,24S)- configuration is critical for maintaining the compound's bioactivity, particularly in inhibiting the NF-κB signaling pathway, which is implicated in various inflammatory diseases.

Another groundbreaking study, featured in *Bioorganic & Medicinal Chemistry Letters*, investigated the anti-cancer mechanisms of Lanost-7-en-3-one,23,24-dihydroxy-25-methoxy-. Using in vitro and in vivo models, the research team found that this compound induces apoptosis in cancer cells by modulating the expression of pro-apoptotic proteins such as Bax and caspase-3. Additionally, the study highlighted the compound's ability to synergize with conventional chemotherapeutic agents, suggesting its potential as an adjunct therapy in cancer treatment.

From a structural perspective, the presence of the 23,24-dihydroxy and 25-methoxy groups in Lanost-7-en-3-one has been identified as a key determinant of its biological activity. A recent *Nature Communications* article detailed the use of X-ray crystallography and NMR spectroscopy to elucidate the compound's three-dimensional structure and its interactions with cellular targets. These findings provide a solid foundation for structure-activity relationship (SAR) studies aimed at developing more potent derivatives.

Despite these advancements, challenges remain in the clinical translation of Lanost-7-en-3-one-based therapies. Issues such as poor solubility and metabolic instability need to be addressed through further chemical modifications and formulation strategies. Ongoing research is also exploring the compound's potential in treating neurodegenerative diseases, given its neuroprotective effects observed in preclinical models.

In conclusion, Lanost-7-en-3-one,23,24-dihydroxy-25-methoxy-, (13a,14b,17a,20S,23R,24S)- (CAS: 115334-04-8) represents a promising scaffold for drug discovery. Its multifaceted biological activities and well-characterized structure make it a valuable candidate for further investigation. Future studies should focus on optimizing its pharmacokinetic properties and expanding its therapeutic applications.

115334-04-8 (Lanost-7-en-3-one,23,24-dihydroxy-25-methoxy-, (13a,14b,17a,20S,23R,24S)-) Related Products

Recommended suppliers
Shandong Feiyang Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shandong Feiyang Chemical Co., Ltd
Shanghai Pearlk Chemicals Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shandong Jing Kun Chemical Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shandong Jing Kun Chemical Co.,Ltd.
Changzhou Guanjia Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Changzhou Guanjia Chemical Co., Ltd
Xiamen PinR Bio-tech Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Xiamen PinR Bio-tech Co., Ltd.